About Neil Kumar
Neil Kumar is a chief executive officer and director at BridgeBio Pharma.
Form D filings name Neil Kumar as a director at TheRas.
Neil Kumar reports to the SEC as a director, officer or major shareholder of 5 public companies, including BridgeBio Oncology Therapeutics (BBOT), Maze Therapeutics (MAZE) and LianBio (LIAN).
Neil Kumar first appears on SEC filings in 2018.
Experience
This experience comes from SEC filings. The years are when the filings name Neil Kumar in the role, so the role may have started earlier or lasted longer.
BI
BridgeBio Pharma, Inc.
Chief Executive Officer and director
2019 – 2026 · Public company (BBIO)
BI
BridgeBio Oncology Therapeutics, Inc.
Director
2025 – 2026 · Public company (BBOT)
MI
Maze Therapeutics, Inc.
Director
2026 · Public company (MAZE)
LI
LianBio
Director
2021 · Public company (LIAN)
EI
Eidos Therapeutics, Inc.
Chief Executive Officer and director
2018 – 2019 · Public company (EIDX)
Key Colleagues at Startups
The people Neil Kumar works with at each company, as listed on that company's latest Form D.
TheRas, Inc. · Form D, May 15, 2024
MD
Michelle Doig
Director
IE
Idan Elmelech
Executive officer
PB
Pedro Beltran
Executive officer
FM
Frank McCormick
Director
EW
Eli Wallace
CEO
RK
Raymond Kelleher
Director